Eb IP Lybrido B.V.
Records under this name other than the patents Eb IP Lybrido B.V. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,669,242 | Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunction Lapsed on the fee record Ended Mar 11, 2026 · USPTO record | Lapsed on the fee record | Ended Mar 11, 2026 | USPTO record |
| US 8,648,060 | Use of 3-alpha-androstanediol in combination with a 5-HT1a agonist, in the treatment of sexual dysfunction Lapsed on the fee record Ended Feb 11, 2026 · USPTO record | Lapsed on the fee record | Ended Feb 11, 2026 | USPTO record |
| US 8,575,139 | Use of testosterone and a 5-HT1a agonist in the treatment of sexual dysfunction Lapsed on the fee record Ended Nov 5, 2025 · USPTO record | Lapsed on the fee record | Ended Nov 5, 2025 | USPTO record |
| US 9,737,548 | Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction Lapsed on the fee record Ended Aug 22, 2025 · USPTO record | Lapsed on the fee record | Ended Aug 22, 2025 | USPTO record |
| US 9,192,669 | Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction Term ended Term ended Jun 30, 2025 · USPTO record | Term ended | Term ended Jun 30, 2025 | USPTO record |
| US 9,700,566 | Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction Term ended Ended no later than May 11, 2025 · USPTO record | Term ended | Ended no later than May 11, 2025 | USPTO record |
| US 10,441,592 | Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction Term ended Ended no later than May 11, 2025 · USPTO record | Term ended | Ended no later than May 11, 2025 | USPTO record |
| US 9,333,203 | Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction Lapsed on the fee record Ended May 10, 2024 · USPTO record | Lapsed on the fee record | Ended May 10, 2024 | USPTO record |
| US 9,211,334 | Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunction Lapsed on the fee record Ended Dec 15, 2023 · USPTO record | Lapsed on the fee record | Ended Dec 15, 2023 | USPTO record |
| US 10,314,848 | Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunction Lapsed on the fee record Ended Jun 11, 2023 · USPTO record | Lapsed on the fee record | Ended Jun 11, 2023 | USPTO record |